New Antimicrobial Agents

作者：Oliphant Catherine M

来源：JNP-Journal for Nurse Practitioners, 2016, 12(3): E91-E100.

DOI：10.1016/j.nurpra.2015.10.008

• ceftazidime/avibactam
• ceftolozane/tazobactam
• dalbavancin
• oritavancin
• tedizolid

Infections caused by resistant pathogens are increasing and are a major threat to patient outcomes. A 2013 US Centers for Disease and Control and Prevention report on antibiotic resistance threats indicates that 2 million Americans acquire antibiotic-resistant infections annually and at least 23,000 die. Increasing resistance of bacterial pathogens to virtually all available antimicrobial classes signals the emergent need for new agents. Only 12 antibiotics were approved by the US Food and Drug Administration between 2000 and 2012. Initiatives to increase the number of effective antibiotics have been enacted. This study addresses the mechanism of action, microbiology, indications, dose, safety, drug interactions, and place in therapy of dalbavancin, tedizolid, oritavancin, ceftolozane/tazobactam, and ceftazidime/avibactam.

• 出版日期2016-3